Sinil Pharmaceutical Co. Ltd (012790) — Cash Flow Quality Index
Sinil Pharmaceutical Co. Ltd (012790) has a Cash Flow Quality Index of 1.01x as of September 2025. Operating cash flow of ₩2.62 Billion exceeds net income of ₩2.61 Billion, indicating high earnings quality where cash backs reported profits. Explore 012790 cash flow metrics to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Sinil Pharmaceutical Co. Ltd Cash Flow Quality Index (2014–2024)
Historical Cash Flow Quality Index for Sinil Pharmaceutical Co. Ltd across 11 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Sinil Pharmaceutical Co. Ltd (012790) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Sinil Pharmaceutical Co. Ltd (2014–2024)
Year-by-year earnings quality comparison for Sinil Pharmaceutical Co. Ltd. For live market cap and the full company financial profile, see Sinil Pharmaceutical Co. Ltd stock valuation.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.59x | ₩22.69 Billion | ₩14.30 Billion | ▲ +42.8% |
| 2023 | 1.11x | ₩15.15 Billion | ₩13.64 Billion | ▼ -1.3% |
| 2022 | 1.13x | ₩13.69 Billion | ₩12.16 Billion | ▼ -32.6% |
| 2021 | 1.67x | ₩11.16 Billion | ₩6.68 Billion | ▲ +14.0% |
| 2020 | 1.47x | ₩11.06 Billion | ₩7.54 Billion | ▼ -13.5% |
| 2019 | 1.70x | ₩12.31 Billion | ₩7.26 Billion | ▲ +5.4% |
| 2018 | 1.61x | ₩9.19 Billion | ₩5.71 Billion | ▲ +52.1% |
| 2017 | 1.06x | ₩8.67 Billion | ₩8.20 Billion | ▼ -12.2% |
| 2016 | 1.20x | ₩12.09 Billion | ₩10.04 Billion | ▲ +10.4% |
| 2015 | 1.09x | ₩9.56 Billion | ₩8.76 Billion | ▲ +19.1% |
| 2014 | 0.92x | ₩9.33 Billion | ₩10.18 Billion | — |